← Back to Search

Brachytherapy

LDR Brachytherapy for Prostate Cancer (PRIAPUS Trial)

N/A
Recruiting
Led By Lucas Mendez, MD
Research Sponsored by Lawson Health Research Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
All pathological cores confined to one lobe of the prostate (minimum of 12 cores sampled), unless a recent multiparametric prostate MR-scan (mpMR) (with < 6 months from the enrollment date) indicates a dominant intra-prostatic lesion (DIL) located at the prostatic lobe where a higher number of cores and Gleason score was found positive. PIRADS v2 score 3-5 lesions are considered DILs.
Biopsy-confirmed adenocarcinoma of the prostate
Timeline
Screening 3 weeks
Treatment Varies
Follow Up until study completion with 5 years of follow up
Awards & highlights

PRIAPUS Trial Summary

This trial is testing a new, MR-guided 3D ultrasound technique to see if it can more effectively treat prostate cancer while sparing the surrounding nerves and vessels.

Who is the study for?
Men with biopsy-confirmed prostate cancer, where the disease is contained in one lobe of the prostate. They should have good erectile function and be sexually active, without severe urinary symptoms or any prior high-risk treatments for prostate cancer. Participants must be fit for anesthesia, under 75 years old, and not have inflammatory bowel disease or certain other medical conditions.Check my eligibility
What is being tested?
The trial is testing a new way to do LDR brachytherapy that uses MR fusion with 3D Ultrasound guidance. The goal is to treat prostate cancer while sparing important nerves and vessels near the prostate and penile bulb to preserve sexual function.See study design
What are the potential side effects?
Potential side effects may include discomfort at the implant site, temporary urinary issues like frequency or urgency, erectile dysfunction risks due to nerve damage during treatment, as well as typical risks associated with anesthesia.

PRIAPUS Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My prostate cancer is confined to one lobe, or a recent scan shows a major lesion there.
Select...
My prostate cancer was confirmed by a biopsy.
Select...
I have no health issues preventing prostate seed implant therapy.
Select...
My prostate cancer is considered low or favorable intermediate risk.
Select...
I am sexually active.

PRIAPUS Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~until study completion with 5 years of follow up
This trial's timeline: 3 weeks for screening, Varies for treatment, and until study completion with 5 years of follow up for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Rate of patients receiving this experimental brachytherapy technique and achieving acceptable dose distribution at 1-month post-implant.
Secondary outcome measures
Acute and long-term GU and GI toxicity
Biochemical failure
Local recurrence
+2 more

PRIAPUS Trial Design

1Treatment groups
Experimental Treatment
Group I: Prostate Cancer PatientsExperimental Treatment1 Intervention
Low- or favourable intermediate-risk prostate cancer patients

Find a Location

Who is running the clinical trial?

Lawson Health Research InstituteLead Sponsor
655 Previous Clinical Trials
413,329 Total Patients Enrolled
15 Trials studying Prostate Cancer
635 Patients Enrolled for Prostate Cancer
Lucas Mendez, MDPrincipal InvestigatorLondon Health Sciences Centre- London Regional Cancer Program

Media Library

UltraSound-guided Low-dose Rate Brachytherapy (Brachytherapy) Clinical Trial Eligibility Overview. Trial Name: NCT04718987 — N/A
Prostate Cancer Research Study Groups: Prostate Cancer Patients
Prostate Cancer Clinical Trial 2023: UltraSound-guided Low-dose Rate Brachytherapy Highlights & Side Effects. Trial Name: NCT04718987 — N/A
UltraSound-guided Low-dose Rate Brachytherapy (Brachytherapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04718987 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any available vacancies for individuals to join the trial?

"Affirmative. Information on clinicaltrials.gov suggests that this research is actively recruiting volunteers, with the original post dating back to June 1st 2021 and a recent update of May 16th 2022. This trial requires 10 participants from just one medical centre."

Answered by AI

Are participants aged over 80 being recruited for this research?

"This clinical trial is targeting patients that are between 18 to 75 years in age. Underage individuals may take part in the 76 trials available, while elderly persons can join one of 1,315 studies designed for them."

Answered by AI

What is the size of the patient cohort participating in this experiment?

"Affirmative. According to the clinicaltrials.gov database, this medical trial is presently enrolling participants and has been since June 1st 2021. The most recent update was on May 16th 2022 and 10 individuals are required from one site for successful recruitment."

Answered by AI

Who would be the ideal candidates for participating in this clinical investigation?

"This medical trial is seeking 10 persons between 18 and 75 years of age who have been diagnosed with prostate cancer. Furthermore, patients must satisfy the following criteria: as classified by National Comprehensive Cancer Network (NCCN), having a low- or favourable intermediate risk; no known contraindications to LDR brachytherapy; minimal erectile dysfunction (a score above 18 in International Index of Erectile Function- 5 [IIEF-5] without PDE-5 inhibitor assistance); biopsy verified adenocarcinoma of the prostate; all pathological cores limited to one lobe unless recent MRI scan (< 6 months from enrollment"

Answered by AI
Recent research and studies
~3 spots leftby Mar 2025